Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK Fusion-positive Non-small Cell Lung Cancer”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Not applicableStudy completedNCT04947683
What this trial is testing

Patient Journey With Advanced Lung Cancer Positive for ALK Fusion in Brazil

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Latin American Cooperative Oncology Group 101
Testing effectiveness (Phase 2)Study completedNCT04042558
What this trial is testing

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Gene Mutation+2 more
Centre Francois Baclesse 150
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05186506
What this trial is testing

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

Who this might be right for
ALK Fusion Protein ExpressionAdjuvant TherapyNon-Small Cell Lung Cancer
Sichuan University 152
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07750704
What this trial is testing

Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC

Who this might be right for
ALK Positive Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 153
Not applicableLooking for participantsNCT04900935
What this trial is testing

Patient-centered, Optimal Integration of Survivorship and Palliative Care

Who this might be right for
Stage IV Non-small Cell Lung CancerTargeted TherapyNonsmall Cell Lung Cancer+5 more
Massachusetts General Hospital 70
Post-approval studies (Phase 4)Not Yet RecruitingNCT07674368
What this trial is testing

Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed

Who this might be right for
ALK Fusion-positive Non-small Cell Lung Cancer
Hunan Cancer Hospital 29
Large-scale testing (Phase 3)Active Not RecruitingNCT02201992
What this trial is testing

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Who this might be right for
ALK Gene RearrangementALK Gene TranslocationALK Positive+5 more
ECOG-ACRIN Cancer Research Group 166
Not applicableStudy completedNCT04087473
What this trial is testing

Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC

Who this might be right for
Non-small Cell Lung CancerALK-Positive Lung Cancer
National Cancer Centre, Singapore 50
Not applicableEnrolling By InvitationNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40